Xeris Pharmaceuticals logo
Xeris Pharmaceuticals XERS

Annual report 2025
added 03-02-2026

report update icon

Xeris Pharmaceuticals Financial Ratios 2011-2026 | XERS

Annual Financial Ratios Xeris Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

1746.1 -11.1 -5.5 -1.9 -1.5 -2.6 -1.2 -3.0 - - - - - - -

P/S

3.3 3.0 2.1 1.6 3.8 11.5 57.1 72.9 - - - - - - -

EPS

- -0.4 -0.5 -0.7 -1.6 -2.1 - - - - - - - - -

EV (Enterprise Value)

1.23 B 887 M 605 M 355 M 330 M 360 M 250 M 224 M 103 M 65.5 M - - - - -

EBITDA per Share

0.16 -0.22 -0.31 -0.59 -1.44 -1.78 -4.65 -4.9 - - - - - - -

EV/EBITDA

-2.6 -3.5 -1.6 -2.8 - - - - - - -

PEG

-26.68 0.26 0.14 - -0.05 -0.34 0.03 - - - - - - -

P/B

70.7 -20.5 -50.5 4.0 2.0 6.9 10.8 2.4 - - - - - - -

P/CF

33.8 -16.4 -7.3 -1.8 -2.0 -2.9 -1.5 -3.1 - - - - - - -

ROE %

4.05 185.16 917.94 -209.49 -128.87 -269.96 -869.91 -79.68 - - - - - - -

ROA %

0.14 -16.97 -19.30 -27.48 -40.32 -57.27 -115.22 -50.05 - - - - - - -

ROCE %

181.87 113.61 648.92 -181.34 -120.92 -63.80 -149.89 -54.02 - - - - - - -

Current Ratio

1.0 0.9 1.0 1.2 1.5 5.4 3.2 11.6 - - - - - - -

DSO

57.2 71.5 78.0 79.9 64.2 122.8 756.1 424.8 - - - - - - -

DIO

500.9 431.1 405.0 345.5 248.3 326.8 495.5 - - - - - - - -

DPO

23.0 68.7 103.0 109.1 122.3 122.0 1275.8 7526.0 - - - - - - -

Operating Cycle

558.1 502.7 483.0 425.5 312.5 449.6 1251.6 424.8 - - - - - - -

Cash Conversion Cycle

535.1 434.0 380.0 316.4 190.2 327.7 -24.2 -7101.1 - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Xeris Pharmaceuticals

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

- -0.01 -0.06 - -0.11 -0.1 -0.14 - -0.09 -0.14 -0.12 - -0.16 -0.19 -0.25 - -0.39 -0.41 -0.3 - -0.35 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

0.06 0.05 -0.02 - -0.07 -0.04 -0.1 - -0.02 -0.1 -0.09 - -0.12 -0.12 -0.21 - -0.35 -0.38 -0.27 - -0.28 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

19.68 147.37 215.18 340.17 24.80 -346.14 -569.40 -516.85 -556.51 -280.81 -170.76 -110.03 946.82 2043.33 1940.39 877.02 829.63 -274.61 -235.11 -254.05 -254.05 -206.66 -107.81 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-8.23 -13.30 -17.25 -15.06 -18.78 -17.60 -19.11 -14.99 -22.20 -25.68 -27.87 -25.41 -45.22 -57.83 -49.62 -19.81 -29.87 -20.11 -20.11 -10.05 -10.05 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-750.67 76.62 142.29 243.18 116.06 -56.57 -216.16 -288.44 -322.56 -229.57 -138.01 -89.85 899.92 1923.80 1819.72 822.39 781.68 -248.79 -119.13 -40.71 -40.71 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

1.0 0.9 0.9 0.9 0.9 0.9 1.0 1.0 1.0 1.0 1.1 1.1 1.2 1.3 1.4 1.5 1.0 - - 1.3 1.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

65.5 63.4 65.8 - 70.3 75.8 86.0 - 71.9 73.3 84.8 - 81.8 88.6 84.4 - 55.9 - 38.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

559.1 460.1 527.3 - 295.7 491.1 609.1 - 415.5 396.0 461.3 - 329.7 329.7 254.5 - 201.8 - 208.7 - 134.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

66.3 60.6 45.2 - 44.5 75.5 142.6 - 131.8 142.6 142.3 - 91.5 168.1 145.6 - 60.8 - 77.9 - 50.2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

624.6 523.4 593.1 - 366.0 566.9 695.1 - 487.4 469.4 546.0 - 411.4 418.3 338.9 - 257.7 - 247.0 - 134.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

558.2 462.8 547.9 - 321.5 491.4 552.5 - 355.6 326.8 403.8 - 320.0 250.2 193.3 - 196.9 - 169.1 - 84.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Xeris Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Grifols, S.A. Grifols, S.A.
GRFS
$ 7.71 1.65 % $ 6.83 B spainSpain
Altimmune Altimmune
ALT
$ 3.5 4.64 % $ 308 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.52 -0.16 % $ 5 B danmarkDanmark
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Heron Therapeutics Heron Therapeutics
HRTX
$ 0.8 2.5 % $ 133 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Immunovant Immunovant
IMVT
$ 24.27 5.61 % $ 3.68 B usaUSA
Incyte Corporation Incyte Corporation
INCY
$ 90.82 0.04 % $ 17.7 B usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 0.79 -3.52 % $ 1.93 M canadaCanada
INmune Bio INmune Bio
INMB
$ 1.23 5.13 % $ 22.1 M usaUSA
Inovio Pharmaceuticals Inovio Pharmaceuticals
INO
$ 1.57 -0.95 % $ 34.8 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.34 14.26 % $ 235 M franceFrance
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
$ 6.09 5.36 % $ 138 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.13 1.91 % $ 199 M israelIsrael
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
$ 16.93 -0.41 % $ 841 M britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
CorMedix CorMedix
CRMD
$ 6.35 1.6 % $ 457 K usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.33 2.12 % $ 719 M canadaCanada
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.33 0.97 % $ 260 M israelIsrael
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA